BP Weighs Sale of Brazilian Biofuels Unit, Signaling Portfolio Trim but Potential Value Loss

What happened

BP is reportedly evaluating options for its Brazilian biofuels business, including a potential sale, according to Bloomberg. This business, known as bp Bunge Bioenergia, was acquired during BP's earlier push into low-carbon energy and contributed to a rise in net debt from $20.9 billion in 2023 to $23.0 billion in 2024. A sale would align with BP's 2025 strategy reset to divest non-core assets and reduce net debt toward $14-18 billion by 2027, as part of the $20 billion disposal program. However, the unit is likely to be sold at a discount to its acquisition cost, given that BP has already taken impairments on transition businesses, which could yield lower-than-expected proceeds and signal past capital misallocation. While the move would further simplify BP's portfolio and focus on hydrocarbons, it also highlights the execution risk in achieving the divestment target at attractive multiples.

Implication

For investors, the news reinforces BP's commitment to divesting non-core assets, but the specific asset being considered was a recent acquisition, suggesting a reversal that may crystallize losses. If the sale proceeds are materially below the original purchase price, it would reduce the total funds available for debt repayment and could pressure the net debt target of $14-18 billion by 2027. Successful execution of this sale, even at a modest price, would still contribute to reducing complexity and refocusing on upstream oil and gas, which is central to the investment thesis. However, repeated instances of buying high and selling low could erode confidence in management's capital allocation discipline, a key factor in the 'potential buy' rating. Investors should track the final terms of any such sale and compare cumulative divestment proceeds against the $20bn target, as shortfalls would warrant a downgrade of the thesis.

Thesis delta

The core thesis of divestment-led deleveraging and hydrocarbon focus remains intact, as this news is consistent with the planned $20bn disposal program. However, the sale of a recently acquired biofuels business raises questions about the quality of past capital allocation and the likely multiple realized. If this and similar divestments come at a discount, the aggregate proceeds may fall short of target, weakening the deleveraging path and potentially reducing the margin of safety.